Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers determine two arthritis medications are safe and effective for children

21.04.2005


An international team of researchers, led by Dr. Earl Silverman of The Hospital for Sick Children (Sick Kids), has found that two arthritis medications (methotrexate and leflunomide) commonly used in adults are safe and effective in children. This research is reported in the April 21, 2005 issue of The New England Journal of Medicine.

"Our study showed that both methotrexate and leflunomide can be used safely and effectively in children. In fact, in our study both drugs had a higher response rate in children than the response rate reported in studies in adults," said Dr. Silverman, the study’s lead author, a rheumatologist and senior associate scientist at Sick Kids, and a professor of Paediatrics at the University of Toronto. "A higher percentage of patients responded to methotrexate, so this would be the medication to try first in children, but leflunomide is a good alternative for patients where methotrexate doesn’t work or isn’t tolerated. Importantly, we have identified a new, safe, effective oral therapy for use in children with chronic arthritis."

The study also showed that a higher dose of methotrexate than previously thought can be used safely in children and that at the increased dose there was increased efficacy. Establishing drug dosages in children is more complicated than adults due to the wide variation in weight between a baby and a teenager.



Patients three to 17 years of age with polyarticular-course rheumatoid arthritis (where arthritis affects at least five joints) were recruited to the study at 32 centres in 13 countries. The children were given either methotrexate or leflunomide, medications that are DMARDs (disease-modifying anti-rheumatic drugs), which work by altering the immune system. Methotrexate is the most commonly used DMARD in children. DMARDs are a stronger class of arthritis medications than NSAIDs (nonsteroidal anti-inflammatory drugs).

"Most medications are never designed for children and are rarely tested in children. However, children do get severe arthritis that requires medications beyond NSAIDs. The only way to properly assess a medication for children is through a randomized, controlled trial. The ’Pediatric Rule’, enacted by the U.S. Congress and supported by the Food and Drug Administration (FDA), has increased the number of drug trials in children with arthritis," added Dr. Silverman.

Juvenile rheumatoid arthritis is a chronic disease that causes pain, stiffness and swelling in more than one joint. It affects approximately one out of every 1,000 Canadian children.

Laura Greer | EurekAlert!
Further information:
http://www.utoronto.ca

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>